Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-25 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.2
Industry P/E
--
EV/EBITDA
1.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
60,583,200
CFO
$-241.59 Mln
EBITDA
$-372.41 Mln
Net Profit
$-309.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
| 402.6 | 729.4 | 640.8 | 252.5 | 25.9 | 3.5 | -42.4 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
| -41.3 | -43.0 | -29.5 | 1.4 | 24.0 | -73.8 | -71.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caladrius Biosciences (CLBS)
|
4.2 | 25.8 | 0.0 | -24.6 | -- | -28.2 | -- | 0.2 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a... recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Read more
Pres, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Pres, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Headquarters
Basking Ridge, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Caladrius Biosciences Inc (CLBS) is $4.23 (NASDAQ) as of 13-Oct-2022 09:30 EDT. Caladrius Biosciences Inc (CLBS) has given a return of 25.89% in the last 3 years.
Since, TTM earnings of Caladrius Biosciences Inc (CLBS) is negative, P/E ratio is not available.
The P/B ratio of Caladrius Biosciences Inc (CLBS) is 0.25 times as on 13-Oct-2022, a 94 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Caladrius Biosciences Inc (CLBS) are Rs -- and Rs -- as of 03-Apr-2026.
Caladrius Biosciences Inc (CLBS) has a market capitalisation of $ 26 Mln as on 13-Oct-2022. As per SEBI classification, it is a company.
Before investing in Caladrius Biosciences Inc (CLBS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.31
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.